Stockscreener 앱 받기
0.2174
0.91%
-0.002
Curanex Pharmaceuticals Inc 주식(CURX)의 최신 뉴스
Curanex Pharmaceuticals Inc Common Stock (NASDAQ: CURX) Stock Price, News & Analysis - Kalkine
Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary - TradingView
CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Curanex Pharmaceuticals (CURX) Jumps 7.33% to $0.20 as Buyers Defend Key Support ZonePrice Target - dars.gov.et
Curanex Pharmaceuticals (CURX) Advances 7.33% as Shares Approach Key Resistance at $0.21Dark Pool Prints - dars.gov.et
Curanex Pharmaceuticals Inc - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.183|Chg%:-0.005 - TradingKey
Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.205|Chg%:+0.014 - TradingKey
Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curanex Pharmaceuticals Inc (CURX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curanex Pharmaceuticals Inc (CURX) Institutional Confidence - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.213|Chg%:+0.008 - tradingkey.com
Curanex Pharmaceuticals Inc (CURX) Cash Flow - TradingKey
Curanex Pharmaceuticals Inc (CURX) Balance Sheet - TradingKey
Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- po-news-eg.net
Curanex Pharmaceuticals Inc Revenue Breakdown – NASDAQ:CURX - TradingView
CURX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Curanex Pharmaceuticals (CURX) Drops 5.73%: Critical Support at $0.20 in PlayChannel Breakout - dars.gov.et
Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23Cup and Handle - dars.gov.et
Curanex Pharmaceuticals (CURX) Edges Higher as Bulls Defend Key $0.26 Support LevelFactor Rotation - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market SessionGain Therapeutics (NASDAQ:GANX), BNB Plus - Benzinga
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
Curanex (CURX) OKs 5.7M-share incentive plan and 1:10–1:50 reverse split - Stock Titan
Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to book forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to sales forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to earnings forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Enterprise value to revenue forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Number of shareholders of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split - Stock Titan
Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks - Bez Kabli
Curanex Pharmaceuticals Inc (CURX) Sees Modest Gain as Shares Test Key LevelsTechnical Analysis Picks - The Legal Advocate
CURXCuranex Pharmaceuticals Inc Stock Price and Quote - Finviz
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - minichart.com.sg
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
0.52%
0.07%
자본화:
|
볼륨(24시간):